Celtarys offers highly specific GLP1R fluorescent ligands, extensively tested in various cell lines, making them ideal for studying the GLP1 receptor in contexts such as type 2 diabetes, weight loss, and kidney disease.
These ligands, developed by Johannes Broichhagen (Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany) and David J. Hodson (Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM)) are licensed to Celtarys, and have been published in peer-reviewed journals.
Celtarys offers selective GLP1 fluorescent antagonists: LUXendin551, LUXendin645 and LUXendin762. They are particularly useful for live cell imaging, receptor activation assays, and studying downstream effects, blood sugar regulation, and cell surface signaling pathways.
Enhance your assays by checking out our dual GLP1R/GIPR fluorescent agonists
-
LUXendin551 GLP1 receptor (GLP1R) fluorescent antagonist (551/576) (CELT-111)
For research use only3 nmol vial that allows to prepare 30 µL of 100 µM stock solution to test GLP1R. One vial is sufficient for injecting one mouse.
Please note that the required concentration may vary depending on the specific assay design.
424,00€ View more -
LUXendin645 GLP1 receptor (GLP1R) fluorescent antagonist (645/664) (CELT-112)
For research use only3 nmol vial that allows to prepare 30 µL of 100 µM stock solution to test GLP1R. One vial is sufficient for injecting one mouse.
Please note that the required concentration may vary depending on the specific assay design.
424,00€ View more -
LUXendin762 GLP1 receptor (GLP1R) fluorescent antagonist (762/784) (CELT-113)
For research use only3 nmol vial that allows to prepare 30 µL of 100 µM stock solution to test GLP1R. One vial is sufficient for injecting one mouse.
Please note that the required concentration may vary depending on the specific assay design.
424,00€ View more
Do you want more information?
We are ready to support your challenges